I think You will ultimately WRONG , so that's where we differ. And now you said - Time will tell!
p.s. FDA FAST TRACK - FACT HISTORY SAID - 80% DRUG is APROVED !!!
Joseph Duato, Executive Vice President and Worldwide Chairman at JNJ, gave us a glimpse into how JNJ thinks regarding an acquisition of a drug like Imetelstat when he answered a question about the acquisition of Actelion.
“
Fundamentally, we looked at these elements of value creation for this acquisition: first, to what extent the new company would bring differentiated platforms or medicines; and to what extent would we be able to reach more patients, be competitive and achieve a stronger portfolio.
Although he was not speaking specifically about Imetelstat, I believe JNJ will use the same line of thinking when they approach a buyout of Geron. Hopefully, this provides some comfort to Geron investors who worry whether or not JNJ will proceed with a buyout. Last week, I analyzed the reasoning behind why I believe JNJ likes the results that Imetelstat has shown so far in clinical trials. Coupled with the reasoning I provided in this article regarding why a buyout makes sense, I believe the reward greatly outweighs the risk. If a buyout were to occur, I believe it could become a 10 bagger at today's prices.
AI
Market Data 
Markets 
